Synapsoft logo
AI Insights from Disclosures
Searching...
IMBiologics Corp. 493280
Searching...

Company Summary

Quarterly Performance Revenue Operating Margin

Market Sentiment

※ Click the graph to view AI analysis information for that month.
Revenue
Consolidated
Separate
Operating Income
Consolidated
Separate
Net Income
Consolidated
Separate

Financials

Excel

No financial data is available for this period.
~
Quarterly
Annual
No data is available for this period.

*Values beyond the fourth decimal place of the unit are displayed as '0/-0'

Financial Indicator Forecast

※ These forecasts are simple AI estimates based on historical data and may differ from actual results.

Company Overview

as of June 2026
IMBiologics Corp. is an innovative antibody drug development company established in August 2020, developing differentiated treatments in the fields of autoimmune disease and immuno-oncology based on its 'Optimal Antibody Modality Construction Technology (IM-OpDECon)'. With a vision of 'launching globally innovative new drugs' and under the slogan Innovative Medicines based on ImmunoModulatory Biologics, the company seeks to meet unmet medical needs that existing treatments have failed to address by utilizing various antibody modalities.
Representative Director Ha Gyeongsik
Founded August 4, 2020
Corporation Type KOSDAQ
Industry Classification Research and experimental development on natural sciences and engineering
Corporate number 13111-0601384
Business number 738-81-01869
Phone Number 031-8067-8172
Fax Number
Website imbiologics.com
Company Address 260 Changnyong-daero, Yeongtong-gu, Suwon-si, Gyeonggi-do

Financial Health

Executives

Employees

Shareholders

Industry revenue

Disclosures

Comments

0 / 255

AI Assistant